Core C: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) This laboratory is a specialized facility at the University of Pittsburgh Cancer Institute (UPCI), which is dedicated to the state-of-the-art evaluation of immune responses prior to, during and after therapeutic interventions in patients with cancer. In addition to generating cellular products for human therapy, it also provides services for tissue procurement and processing. In its role as Core C for this PPG, the IMCPL will assume responsibility for supporting the immunotherapy-based clinical trials proposed by the projects. Core C, functioning as a cGMP facility, will culture and characterize dendritic cells (aDC1) for patient therapy and prepare vaccines by loading these aDC1 with apoptotic tumor cells (ATC) (colorectal cancer (Project 1 and 4) and melanoma (Project 1)) for therapy. Core C will be responsible for quality and sterility of the aDC1- based vaccines. Potency of aDC1 products will be measured, using the IL-12p70 production assay. Core C will also procure and process all body fluids and tissues harvested in the course of the clinical trials. Tumor specimens obtained at the time of surgery or biopsy tissues will be processed for use in vaccines or will be banked for immunohistochemistry to be performed by Core B. Core C, serving as a fully certified immunologic monitoring facility, will monitor immune responses to the administered vaccines by performing ELISPOT assays and tetramer analyses. Core C will also be prepared to assist the PPG investigators in implementing assays necessary for evaluation of immunologic responses to vaccines. The Core will ensure that all cellular products it generates and samples it collects are accompanied by appropriate documentation that will permit linking laboratory analyses with clinical results. Core C will also provide assistance in preparation of IND submissions. The Core laboratory has a long history of collaboration with all of the investigators, and in the context of the proposed clinical and pre-clinical studies will be entirely dedicated to the support of this PPG.

Public Health Relevance

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA132714-05
Application #
8469296
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$436,178
Indirect Cost
$147,601
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Liu, Zuqiang; Ravindranathan, Roshni; Kalinski, Pawel et al. (2017) Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 8:14754
Wong, Jeffrey L; Obermajer, NataĊĦa; Odunsi, Kunle et al. (2016) Synergistic COX2 Induction by IFN? and TNF? Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res 4:303-11
Downs-Canner, Stephanie; Guo, Zong Sheng; Ravindranathan, Roshni et al. (2016) Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther 24:1492-501
Muthuswamy, Ravikumar; Corman, John M; Dahl, Kathryn et al. (2016) Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Prostate 76:1095-105
Francis, Lily; Guo, Zong Sheng; Liu, Zuqiang et al. (2016) Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget 7:22174-85
Radomski, Michal; Zeh, Herbert J; Edington, Howard D et al. (2016) Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. J Immunother Cancer 4:24
Kalinski, Pawel; Gingrich, Jeffrey R (2015) Toward improved effectiveness of bladder cancer immunotherapy. Immunotherapy 7:1039-42
Zeh, Herbert J; Downs-Canner, Stephanie; McCart, J Andrea et al. (2015) First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther 23:202-14
Liu, J Y; Li, F; Wang, L P et al. (2015) CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer 113:747-55
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94

Showing the most recent 10 out of 59 publications